Key Takeaways The claim that postbiotic dog supplements lack enough clinical evidence to recommend them is rated Misleading. Product-level canine randomized controlled trials (RCTs) do exist in the postbiotic category — PMID 40509062 (oral health) and PMID 40723482 (gut-skin axis) are two direct examples. Mechanism studies and ingredient-level trials should not be conflated with finished-product…

Key Takeaways The claim “no probiotics means no gut support” conflates mechanism with ingredient class — peer-reviewed evidence shows postbiotic metabolites and prebiotic fibers can independently support canine gut health. Two PubMed-indexed canine trials (PMID 40509062, 40723482) document measurable outcomes from formulations containing no live probiotic cultures. Prebiotic fermentable fiber (FOS, GOS, MOS, inulin) drives…

Key Takeaways The NASC Quality Seal certifies manufacturing quality and label-claim adherence — it does not certify that a dog supplement is clinically effective for any specific health outcome. NASC audit criteria (Good Manufacturing Practices, adverse-event reporting, label accuracy) are categorically different from randomized controlled trial (RCT) evidence demonstrating product efficacy. Owners weighing dog supplement…

Key Takeaways The claim that a higher CFU number on a dog supplement label equals a stronger product conflates “counted at manufacture” with “viable at point of sale” — two very different numbers. CFU-based dosing depends on bacterial survival through manufacturing, shelf life, chewing, stomach acid, and intestinal transit — a chain with multiple failure…

Key Takeaways The claim that postbiotics are “just probiotics with the bacteria removed” misrepresents how postbiotics are manufactured and how they act. Postbiotics are deliberately prepared inactivated microbial cells or cell fractions that retain measurable biological activity — they are not waste products. Mechanism literature distinguishes soluble metabolites (short-chain fatty acids, peptides), structural cell components,…

Key Takeaways The claim that “dog supplements without proprietary blends are less potent” conflates brand secrecy with pharmacological potency — the two are unrelated. Full dose disclosure allows evidence-based evaluation against published clinical literature; proprietary blends hide the very data needed for assessment. Veterinary pharmacology principles support transparency: dose-response relationships cannot be verified without knowing…

Key Takeaways The claim that an oral-health dog supplement must contain live probiotics is not supported by the current dental microbiome literature. Postbiotic metabolites — short-chain fatty acids, bacteriocins, organic acids, peptides — can modulate the oral microbiome and support dental outcomes without delivering live organisms. The canine oral-health RCT registered as PMID 40509062 used…

Key Takeaways The claim “a higher CFU number means a better dog probiotic” is misleading because CFU values printed on labels describe the count at the time of manufacture, not at the point of delivery. Published stability studies on canine and human probiotic products show measurable CFU losses during shelf life, often exceeding 50% by…

Key Takeaways The claim that live probiotic cultures are “always superior” to postbiotics in dogs fails on three points: (1) no peer-reviewed canine trial has compared matched live vs. postbiotic formulations head-to-head, (2) CFU counts on labels do not guarantee viability at the point of sale, and (3) postbiotics carry documented mechanism-of-action evidence independent of…

Key Takeaways Soft chew format introduces documented heat, moisture, and mechanical stressors that challenge live CFU viability from manufacture through shelf life. No peer-reviewed canine-specific stability data exists validating soft chew CFU counts at the point of consumption. The claim that soft chews are the “best” delivery format is unsupported by stability evidence — it…